Tolterodine
- Generic Name
- Tolterodine
- Brand Names
- Detrol, Detrusitol
- Drug Type
- Small Molecule
- Chemical Formula
- C22H31NO
- CAS Number
- 124937-51-5
- Unique Ingredient Identifier
- WHE7A56U7K
- Background
Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.
- Indication
For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
- Associated Conditions
- Urinary Urge Incontinence
Bladder Wall Blood Perfusion Pattern and Sexual Dysfunction in Female Patients With Lower Urinary Tract Symptoms, and the Association of That Perfusion Pattern and Therapeutic Efficacy of Antimuscarincs for Female Overactive Bladder Syndrome.
- First Posted Date
- 2011-01-25
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Far Eastern Memorial Hospital
- Target Recruit Count
- 676
- Registration Number
- NCT01282840
- Locations
- 🇨🇳
Far Eastern Memorial Hospital, New Taipei, Banqiao, Taiwan
STUDY The Effect of HNF-4A G60D Variant on the In VIVO CYP2D6 Activity By Tolterodine Pharmacokinetic Study
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2010-08-13
- Lead Sponsor
- Inje University
- Target Recruit Count
- 31
- Registration Number
- NCT01181505
Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)
- Conditions
- Low Back Pain
- Interventions
- First Posted Date
- 2010-08-11
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 150
- Registration Number
- NCT01179828
- Locations
- 🇨🇭
Andreas Siegenthaler, Dep. of Anesthesiolgy and Pain therapy, Bern University Hospital, Switzerland
Combined Behavioral and Drug Treatment of Overactive Bladder in Men
- Conditions
- Overactive BladderLower Urinary Tract Symptoms
- Interventions
- Behavioral: Behavioral trainingOther: Combined Behavioral + Drug Therapy
- First Posted Date
- 2010-08-04
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 204
- Registration Number
- NCT01175382
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸University of Texas Health Science Center San Antonio, San Antonio, Texas, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
A Study of YM178 in Subjects With Symptoms of Overactive Bladder
- Conditions
- Urinary Bladder, Overactive
- Interventions
- First Posted Date
- 2010-01-07
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 1126
- Registration Number
- NCT01043666
Effects of Novel Combinations of Tolterodine/Pilocarpine on Pharmacokinetics (PK) and Pharmacodynamics (PD) of Tolterodine in Healthy Subjects
- Conditions
- Incontinence
- Interventions
- First Posted Date
- 2009-12-21
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- TheraVida, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT01036035
Effects of GABA-a-Agonists on Pain Mechanisms: An Experimental Study in Healthy Volunteers
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2010-08-11
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 17
- Registration Number
- NCT01011036
- Locations
- 🇨🇭
Dep of Anesthesiology and Pain Therapy, University Hospital Bern, Bern, Switzerland
A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2009-10-29
- Last Posted Date
- 2010-07-27
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 750
- Registration Number
- NCT01004315
- Locations
- 🇯🇵
Japan, Hokkaido,Tohoku,Kanto,Chubu,Kansai,Shikoku,Kyushu, Japan
A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder
- Conditions
- Urinary Bladder, Overactive
- Interventions
- First Posted Date
- 2009-08-26
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 1139
- Registration Number
- NCT00966004
Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)
- Conditions
- Benign Prostatic Hyperplasia (BPH)
- Interventions
- First Posted Date
- 2009-07-14
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- Siami, Paul F., M.D.
- Target Recruit Count
- 46
- Registration Number
- NCT00939120
- Locations
- 🇺🇸
Deaconess Clinic Gateway Health Center, Newburgh, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.